Trial Profile
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jun 2022
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Cytarabine; Dasatinib; Doxorubicin; Mercaptopurine; Methotrexate; Prednisone; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Jun 2022 Results assessing the safety of adding ixazomib, an oral proteasome inhibitor, to a multi-agent treatment regimen for older adults with acute lymphoblastic leukemia (ALL) published in the Leukemia and Lymphoma
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.